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Abstract 
Analysing the results of the Motilium treatment of women in reproductive age different internal 
medical diseases, the authors discuss the possibility of a new kind of nonhormonal ovulation-inhibitory 
anticonception. Domperidon preparation have been used as antiemetic and for induction of lactation. 
This agent increases the seruM prolactin level in early pregnancy, in puerperas and menopause. The 
results of endocrinologie study of the 3 women treated for gastrointestinal complaints with 3 x 10 mg 
domperidon are discussed. The analysis of the protein and steroid hormon values determined during 
treatment, as well as the basal temperature curves indicated anovulatory menstruation. In the authors 
opinion treatment with dopamine antagonists with subsequent elevation of prolactin level makes the 
ovulation-inhibitory oral contraceptives unnecessary. They expect that dopamine antagonists will 
substitute hormonal contraceptives and eliminate the undesirable side-effects of the latter. Cessation of 
treatment quickly reverses the effect, indicating the reversible character of the increase of prolactin level. 
The authors also assume that dopamine antagonists will substitute high-dose progesterone presently 
used for postcoital contraception. Precoital treatment with dopamine antagonists abolishes or postpones 
ovulation. 
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Introduction 
Combined oral contraceptive tablets introduced more than three decades ago 
were supposed to solve the problem of birth regulation. However the agents with 
high level of active substances damaged not only the reproductive system, but also 
the whole organism. 
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The use of hormonal contraceptive tablets frequently elicited infertility or 
damages of the cycle by affecting the endometrial structures or inducing 
hyperprolactinemia (BROUWERS et al., 1980). 
Taking oral contraceptive tablets is a serious risk factor in family planning. 
Furthermore these tablets also lead to the developement of vascular diseases 
(COBRIN et al., 1985). 
Several new aspects of contraception providing better family planning in future 
came up. 
The Moti l ium preparation produced by the Richter Pharmacological Works 
contains 10 mg domperidon and is used as antiemetic and lactation-inducing drug. 
This drug was found to elevate the serum prolactin level in pregnants, puerperas 
and women in menopause (FARKAS, 1989; FARKAS et al., 1989). 
Can domperidon as a dopamin inhibitor which elevates the serum prolactin level 
inhibit the ovulation in the physiological cycle? 
If the answer is positive, then taking the dopamine inhibitors makes oral 
contraceptives unnecessary and even deleterious. The wide use of these drugs is 
expected in neurology and internal medicine. 
Pharmacological and biological effects of domperidon 
Chemical structure of domperidon is 
similar to that of neuroleptics (Fig. 1.). It 
also elevates the serum prolactin level but 
does not penetrate via the blood brain bar-
rier. In rare cases this agent induces masto-
dynia or galactorrhea. 
Cessation of treatment with this sub-
stance normalizes the serum prolactin level. 
Domperidon is a new antidopamine pre-
paration. It stimulates prolactin secretion in 
hypophysis independently of the applied 
dose. The domperidon-induced prolactin 
secretion is higher in luteal than in follicu-
lar phase of a normal cycle. It can interfer 
with the menstrual cycle, but does not af-
fect the fertility in males. 
Metoclopramid inhibits both the periferal and the central dopaminreceptors. 
Following treatment with both agents, there was a 10-fold increase in serum 
prolactin level. Long-time metoclopramid treatment further elevates the prolactin 
values (a 25-fold increase), while long-term taking o f omperidon decrease the serum 
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Figure 1. Chemical structure of 
domperidon and haloperidol. 
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prolactin level below the normal values (a 6-fold decrease) (BROUWERS et al., 
1980.). 
Dopamine itself is a prolactin-inhibiting factor (PIF). Special very short tubero-
infundibular dopaminergic neurons (TIDA) have been found in the vicinity of 
eminentia mediana (FUXE, 1964). 
Somatropine and prolactin have a definite rhythm. The question arises whether 
it is a real endogenous rhythm? 
There is a close relationship between the secretion of these hormones and 
periods of sleep. Somatotropin secretion is elevated in the early phase of sleep 
(during the first two hours) and is followed by a marked increase of its serum 
concentration. By the third hour the concentration of this hormon decreases to 0. 
The prolactin rhythm differs from that of somatotropin, for the prolactin level 
reaches its maximal values by the end of the sleeping period. T h e oscillation 
amplitude for somatotropin is about 5 units and for prolactin 1 unit ( W l S S E R and 
B R E U E R , 1981). 
Materials and methods 
W e have treated three women of reproductive age for gastrointestinal symptoms (emesis, nausea) 
and disturbances of gastric motility with daily 3 tables of domperidon (3 x 10 mg). Their first 
mentsruation occured at the age of 13-14. All the patients were 20-37 years old. T h e y menstruated 
every 28 days for 4 - 5 days. O n e patient have already had 2 children, the rest have not yet been 
pregnant, but had stable cycle. Thus their fertility can also be considered as a proved. Neither patient 
took contraceptive drugs, all of them used biological methods. 
Fasted venous blood samples have been taken on the day 6 before-, and days 9, 14 and 22 during 
treatment. Following centrifugation, the serum was stored at - 2 0 C ° . 
Prolactin, FSH, LH and 17-beta-oestradiol levels were determined with R I A ( I Z I N T A M T A K I T T ) . 
During the period of treatment all the patients had normal sexual life and did not use contraceptive 
drugs. During the cycle they measured their basal temperature and plotted temperature curves. 
W e compared the results of domperidon treatment to those following treatment with three-phasic 
T R I - R E G O L tablets, because the new substance contains less oestrogen. 
Results 
Compared to the controls, the serum prolactin values on the 22nd day of the 
cycle were elevated in all three patients. In 2 cases these values exceeded 500 mIU/1 
(Fig. 2.). 
In one case the F S H level increased from 5,3 IU/1 to 14,7 IU/1 by the 22nd day 
of the cycle. In two other cases its values remained around 10 IU/1 both in the 
follicular and luteal phases (Fig. 3.). 
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0 „ in serum prolactin level due to domperidon treatment from 
day 6 until day 22 of the cycle ( n - 3 ) . (Before T R I - R E G O L treatment x 
+/-SD, n - 13) 
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Figure 3. Change in serum FSH concentration due to domperidon treatment 
from day 6 until day 22 of the cycle, ( n - 3 ) (Before T R I - R E G O L 
treatment x +/-SD, n - 1 3 ) 
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from day 6 until day 22 of the cycle, ( n - 3 ) . (Before T R I - R E G O L 
treatment x + / - S D , n - 1 3 ) 
from day 6 until day 22 of the cycle, ( n - 3 ) . (Before T R I - R E G O L 
treatment x + / - S D , n— 13) 
There was a lack of LH-peakat on the 14lh day, however in 2 patients its con-
centration by the 22nd day exceeded the levels detected before treatment (Fig. 4.). 
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The 17-beta-oestradiol level markedly decreased and did not show typical 
„double-peaked" physiological curve (Fig. 5.). 
Serum progesteron level remained within the physiological range both in the 
follicular and luteal period (Fig. 6.) 
R E G O L treatment x +/-SD, n - 1 3 ) 
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Serum prolactin, FSH, LH, progesterone and 17-beta-oestradiol levels during the 
cycle under T R I - R E G O L treatment (x +/-SD, n = 1 3 ) (Fig. 7). 
The basic temperature curve of the patients was monophasic, typical of 
unovulatory cycles. Pregnancy occured in none of the cases and the menstruation 
cycle was restored. 
Discussion 
Female hypothalamic-hypophyseal regulation occurs at two levels. The lower 
level is regulated by the releasing factors and is known in literature as a tonic 
mechanism (FLERKO, 1 9 6 2 ) . Neural cyclic regulation is considered as an upper 
level. Szontagh ( 1 9 7 6 ) found that lower progesteron levels affect the cyclic 
mechanism by inhibiting the releasing factor thus leading to a transient infertility. 
Prolactin release is inhibited by hypothalamic dopamine. Some literary data 
indicate that prolactin regulates its release not only at the hypothalamic, but also 
at the hypohyseal level. That means that prolactin inhibits the hormon secreting 
activitiy of the hypophyseal lactotropic cells (HERBERT et al., 1979). 
Domperidon as a dopamin inhibitor enhances prolactin secretion. The serum 
prolactin values become higher at the luteal phase of the ovulation cycle, compared 
to the follicular stage. Treatment with biphasic contraceptive tablets (Anteovin) 
fails to show such difference between the stages of the cycle, however the mean 
prolactin values were significantly lower, than in control cycles ( F A R K A S , 1 9 8 8 ; 
F A R K A S et al., 1 9 8 6 ) . Sas (SAS and F A R K A S , 1 9 7 9 ) showed that the luteal 
progesteron release is markedly lower, if plasma prolactin level is inhibited by 
bromocryptin to the values below 3 ng/ml (1 ng/ml = 32.5 IU/1). It seems that 
under physiological conditions prolactin plays no important role in ovulation. 
However if prolactin concentration is increased by domperidon or lowered below 
a certain level by bromocryptin, anovulation occurs. A further increase of 
concentration of the active substance not elevate the prolactin level. The effect will 
quickly reverse after cessation of treatment, indicating the reversibility of the 
increased prolactin level ( F A R K A S et al., 1 9 8 9 ) . 
Treatment started from the 6 ,h day of the cycle with 30 mg/day domperidon 
would abolish the L H peak typical of the ovulation. Pregnancy did not occur. Our 
patients had regular menstruation in regular time. 
Despite the fact that our study has been performed only on 3 patients, we could 
clearly indicate that domperidon treatment elevates the serum prolactin level, 
abolishes the LH-peak and induces anovulatory menstruation. T o clarify the 
anovulatory mechanisms elicited by dopamin inhibitor, further collection of data, 
wider clinical and laboratory studies are necessary. 
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Our data indicate that in women of reproductive age treated for gastrointestinal 
complaints with domperidon, oral anticonception becomes unnecessary. We expect 
that introduction of dopamine antagonists instead of hormonal anticonceptives 
woul overcome the pathological side-effects elicited by the latter on the reproduc-
tive system and the whole organism. Other dopamine antagonists substances could 
possibly solve the problem of postcoital anticonception, substituting the high doses 
of progesteron. Our results in this field will be published later. 
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